Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 18/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357695 | 0.85 | MEN1 (0.44) | MEN1APAF1NPC1PLA2G1BHSP90AA1 | |
| SCHEMBL5517313 | 0.83 | MEN1 (0.42) | MEN1APAF1NPC1PLA2G1BHSP90AA1 | |
| SCHEMBL1735070 | 0.83 | MEN1 (0.49) | MEN1APAF1NPC1PLA2G1BHSP90AA1 | |
| SCHEMBL357535 | 0.82 | MEN1 (0.46) | MEN1APAF1NPC1PLA2G1BHSP90AA1 | |
| SCHEMBL2869707 | 0.82 | MEN1 (0.48) | MEN1APAF1NPC1PLA2G1BHSP90AA1 | |
| Hydrochloric Acid SCHEMBL3426404 | 0.81 | MEN1 (0.45) | MEN1APAF1NPC1PLA2G1BHSP90AA1 | |
| Trifluoromethanesulfonic Acid SCHEMBL29390371 | 0.81 | MEN1 (0.58) | MEN1APAF1NPC1PLA2G1BHSP90AA1 | |
| Trifluoromethanesulfonic Acid SCHEMBL294105 | 0.81 | MEN1 (0.58) | MEN1APAF1NPC1PLA2G1BHSP90AA1 | |
| SCHEMBL358056 | 0.81 | MEN1 (0.49) | MEN1APAF1NPC1PLA2G1BHSP90AA1 | |
| SCHEMBL357140 | 0.80 | MEN1 (0.51) | MEN1APAF1NPC1PLA2G1BHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021276-B1 | PROCESS FOR PURIFYING PERFLUORINATED PRODUCTS | DU PONT (US) | 2013-07-17 | — | — | EP | claimed |
| US-20100143993-A1 | PROCESS FOR FERMENTIVE PREPARATIONFOR ALCOLHOLS AND RECOVERY OF PRODUCT | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-06-10 | — | — | US | claimed |
| US-20100143999-A1 | PROCESS FOR FERMENTIVE PREPARATION OF ALCOHOLS AND RECOVERY OF PRODUCT | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-06-10 | — | — | US | claimed |
| US-20100139154-A1 | PROCESS FOR FERMENTIVE PREPARATION OF ALCOHOLS AND RECOVERY OF PRODUCT | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-06-10 | — | — | US | claimed |
| US-20100143994-A1 | PROCESS FOR FERMENTIVE PREPARATION OF ALCOHOLS AND RECOVERY OF PRODUCT | E. I. DU PONT DE MEMOURS AND COMPANY | 2010-06-10 | — | — | US | claimed |
| US-20200129922-A1 | METHOD OF REDUCING CONCENTRATION OF FLUORINE-CONTAINING COMPOUND IN SAMPLE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-04-30 | — | — | US | disclosed |
| US-8771626-B2 | Process for purifying perfluorinated products | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-07-08 | — | — | US | disclosed |
| US-8715521-B2 | Absorption cycle utilizing ionic liquid as working fluid | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8707720-B2 | Hybrid vapor compression-absorption cycle | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-04-29 | — | — | US | disclosed |
| US-8628644-B2 | Utilizing ionic liquids for hydrofluorocarbon separation | E I DU PONT NEMOURS AND COMPANY (US) | 2014-01-14 | — | — | US | disclosed |
| US-8568608-B2 | Vapor compression cycle utilizing ionic liquid as compressor lubricant | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2021276-B1 | PROCESS FOR PURIFYING PERFLUORINATED PRODUCTS | DU PONT (US) | 2013-07-17 | — | — | EP | disclosed |
| WO-2007143051-A2 | VAPOR COMPRESSION UTILIZING IONIC LIQUID AS COMPRESSOR LUBRICANT | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-12-13 | — | — | WO | disclosed |
| EP-1846535-A1 | ABSORPTION CYCLE UTILIZING IONIC LIQUID AS WORKING FLUID | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20070131535-A1 | Utilizing ionic liquids for hydrofluorocarbon separation | THE CHEMOURS COMPANY FC, LLC | 2007-06-14 | — | — | US | disclosed |
| WO-2007038363-A2 | UTILIZING IONIC LIQUIDS FOR HYDROFLUOROCARBON SEPARATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070019708-A1 | Hybrid vapor compression-absorption cycle | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-01-25 | — | — | US | disclosed |
| WO-2006124776-A2 | HYBRID VAPOR COMPRESSION-ABSORPTION CYCLE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060197053-A1 | Absorption cycle utilizing ionic liquid as working fluid | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-09-07 | — | — | US | disclosed |
| WO-2006084262-A1 | ABSORPTION CYCLE UTILIZING IONIC LIQUID AS WORKING FLUID | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070131535-A1 | Utilizing ionic liquids for hydrofluorocarbon separation | AQP3, AQP1, SLC26A3 | MEN1 995/4885APAF1 1757/4885NPC1 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.